Log in

130A Veritas In Silico Inc. TSE · Japan

Veritas In Silico (130A) news

Veritas In Silico Inc. is a public biotech or pharmaceutical company listed on TSE under the ticker 130A, recorded under Japan. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Veritas In Silico news

We have not published a story on Veritas In Silico yet. When there is news, it will appear here.

Questions about Veritas In Silico

What is the ticker symbol of Veritas In Silico?

Veritas In Silico Inc. trades under the ticker 130A on TSE.

Where is Veritas In Silico listed?

Veritas In Silico Inc. is listed on TSE.

Which country or territory is Veritas In Silico listed under?

Our directory records Veritas In Silico Inc. under Japan.

What does Veritas In Silico do?

Our directory classifies Veritas In Silico Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Veritas In Silico?

The ISIN recorded for Veritas In Silico Inc. is JP3155340007.

Does aibio.space cover Veritas In Silico?

aibio.space lists Veritas In Silico Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Veritas In Silico?

Companies in our directory listed in the same country and business area as Veritas In Silico: Peptidream, Chiome Bioscience, J-Pharma Co.,Ltd., Kidswell Bio, PRISM BioLab Co. LTD, Human Metabolome Technologies.

Investor discussion: Veritas In Silico

Members talk about Veritas In Silico (130A). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TSE:130A on TradingView.

Listing details

Veritas In Silico Inc. is a public biotech or pharmaceutical company listed on TSE under the ticker 130A, recorded under Japan. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Veritas In Silico Inc.
Ticker
130A
Listing
TSE
Country or territory
Japan
Business scope
Biotechnology
ISIN
JP3155340007
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.